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Background: One key step in the development of prostate cancer (PCa) metastasis is the loss of E-cadherin
expression associated with increased cellular motility and tumor invasion. This loss of E-cadherin expression is also
required during normal embryogenesis and similar transcriptional repressors have been identified in both processes.
We have previously reported the presence of one such transcription factor, WT1 in high Gleason grade prostate
tumor tissues, and its absence in non-neoplastic or benign prostatic hyperplasia tissues.
Results: To better understand the effect of WT1 on E-cadherin expression and migration of PCa cells we quantified
WT1 and E-cadherin mRNA levels in normal prostate epithelial and PCa cell lines with varying migratory potential.
In WT1 transfected cells E-cadherin transcript levels were decreased, while they were increased in siWT1-RNA
transfected PCa cells, suggesting that elevated WT1 expression was sufficient to dampen E-cadherin levels and
potentially enhance migratory ability. To delineate the mechanism of WT1-mediated repression of E-cadherin,
potential WT1 binding sites were tested in vitro and in vivo binding of WT1 to the E-cadherin promoter in the
chromatin of LNCaP and PC3 cells was assessed by Chromatin Immunoprecipitation. The effect of WT1 binding was
measured in reporter assays; in PC3 and DU145 cells WT1 decreased the activity of the proximal E-cadherin
promoter. Using site-directed mutagenesis, a newly identified WT1 binding site located 146 bp from the
transcription start site was shown to be required for this repression by WT1. Transwell migration and wound
healing assays revealed that in LNCaP cells with low migratory potential, over-expression of WT1 was sufficient to
enhance migration, conversely, in the highly migratory PC3 cells silencing of WT1 decreased migration.
Conclusions: These findings suggested that WT1 expression in high grade prostate cancer may contribute to
migration and metastasis. Thus, in prostate cancer WT1 may function as a novel oncogene facilitating development
of the lethal metastatic phenotype.
Keywords: WT1, E-cadherin, Prostate cancer, Migration, MetastasisBackground
Prostate cancer (PCa) is the second leading cause of
cancer death among men in the USA [1]. Although
patients with localized prostate cancer have high
survival and relative low mortality rate, patients with
detectable metastases have median survival of 12–
15 months, suggesting that metastatic process is the
main cause of high mortality among PCa patients [2].
The loss of cell adhesion is a crucial step in the process* Correspondence: gfraizer@kent.edu
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reproduction in any medium, provided the orof metastasis and a critical early event is the conversion
of the stationary to the migratory phenotype [3]. When
cancer cells acquire motility and invasiveness, they
undergo drastic changes in their structure: lose epithe-
lial features, such as adhesion, and acquire a more mes-
enchymal phenotype. This modification of cancer cells
is known as the epithelial to mesenchymal transition
(EMT) [4,5] and the loss of cell-cell interaction is
caused by suppression of cell adhesion molecules such
as E-cadherin, normally expressed by epithelial cells.
Loss or down regulation of E-cadherin expression is
associated with an increase in the migration andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prostate [7-10].
Down regulation of E-cadherin has been reported to
occur via hypermethylation [11,12], mutations [13] and
transcription factors such as Snail [14,15], Slug [16],
ZEB-1 and ZEB-2(SIP-1) [17] and the bHLH family of
factors E12/E47 and Twist [18,19]. E-cadherin has also
been shown to be regulated by the zinc finger tran-
scription factor WT1 in NIH3T3 fibroblasts [20] and
in cardiac epithelial cells undergoing EMT, WT1
represses E-cadherin expression both directly and in-
directly by the upregulation of the repressor Snail [21].
Although multiple isoforms of WT1 have been identi-
fied, those that regulate transcription lack a tripeptide
(KTS) insertion in exon 9 [22]. Our study focuses on
identifying the function of the transcriptionally active
isoform lacking both exon 5 and KTS in prostate can-
cer cells. WT1 was first identified as a tumor suppres-
sor based on its mutational inactivation in Wilms’
tumors of the kidney [23]. In contrast, in other tumor
types, WT1 levels are elevated, suggesting an onco-
genic role [24-30]. In PCa, it has been reported that
WT1 is a marker of human PCa progression [29], and
that WT1 is primarily expressed in high Gleason grade
PCa epithelial cells [30]. However the relationship of
WT1 to E-cadherin expression in PCa has not been
characterized.
Here we tested the effect of WT1 on endogenous
E-cadherin mRNA levels by both silencing and over-
expressing WT1. Potential WT1 binding sites in the E-
cadherin promoter were characterized using chromatin
immunoprecipitation (ChIP) and site-directed mutagen-
esis. The biological impact of WT1-mediated repression
of E-cadherin was tested by migration and wound healing
assays in PCa cells with varying migratory potential.
Overall, this study was designed to determine whether
WT1 transcriptionally regulated E-cadherin and thereby,
migration of PCa cells.
Results
Transcriptional repression of E-cadherin is mediated
through a novel WT1 binding site in the E-cadherin
proximal promoter
Previous studies in our lab demonstrated differences in
WT1 mRNA levels between normal prostate epithelial
(RWPE-1) and PCa cell lines [30] and others have
reported that E-cadherin protein levels were higher in
LNCaP than PC3 [31]. Thus, we analyzed whether WT1
and E-cadherin mRNA levels were inversely related in
these cell lines. Quantitative real-time PCR (qRT-PCR)
was performed to measure the levels of WT1 and
E-cadherin mRNA in these PCa cell lines. As expected, we
found that WT1 (Figure 1A) and E-cadherin (Figure 1B)
mRNA levels were inversely related. This inverserelationship is consistent with reports of others that WT1
is a regulator of E-cadherin in NIH 3T3 [20] and epicar-
dial cells [21]. To determine whether WT1 is a regulator
of E-cadherin gene expression in LNCaP and PC3 PCa
cells, we transfected the cells with pCMV4 or GFP/WT1
expression vector and measured the effect of WT1
overexpression by TaqMan qRT-PCR as described below.
Our results showed that GFP/WT1 transfection reduced
E-cadherin mRNA levels 2-fold in LNCaP (Figure 1C) and
1.7-fold in PC3 (Figure 1D) cells compared with pCMV4
transfected cells. These results were reproduced thrice
and consistently showed that increased WT1 expression
(≥10-fold) is sufficient to repress E-cadherin mRNA levels.
To determine the effect of decreased WT1 levels on
E-cadherin regulation, we transfected LNCaP and PC3
cells with scrambled (RISC) or targeted siWT1 RNA
oligonucleotides (Dharmacon) or no RNA (MOCK). The
levels of WT1 and E-cadherin mRNA were measured
using TaqMan qRT-PCR. Transfection with siWT1 RNA
oligonucleotide #7 (Dharmacon) reduced WT1 mRNA
levels by 88% in PC3 and 81% in LNCaP cells (data not
shown). The suppression of WT1 expression increased
the levels of E-cadherin mRNA 5-fold in siWT1 RNA
oligonucleotide transfected LNCaP (Figure 1E), and 2-fold
in PC3 cells (Figure 1F) cells compared to the scramble
oligonucleotides (RISC). These results were reproduced in
three independent experiments with similar findings. Add-
itionally, results with oligonucleotide #7 (Dharmacon)
were confirmed using a differently targeted siWT1 RNA
oligonucleotide, #8 (Dharmacon) that also similarly
decreased WT1 mRNA levels by 81% and increased
E-cadherin mRNA levels in PC3 cells by 1.9-fold (data not
shown). Surprisingly WT1 protein levels were less strongly
affected by siRNA oligonucleotides and thus E-cadherin
protein levels were only modestly increased (data not
shown). Overall, these results showed that E-cadherin
transcript levels were inversely affected by WT1 over-
expression and siWT1 RNA knock-down in these two
PCa cell lines.
To determine how WT1 might regulate E-cadherin
expression we identified potential WT1 binding sites in
the E-cadherin promoter, using the MatInspector
software. We identified two potential WT1 binding sites
at −15 and −146 bp upstream from the transcription start
site (Figure 2A). A third WT1 binding site at −51 bp was
previously reported functional in fibroblasts [20] but not
identified by the MatInspector software (Figure 2A).
Moreover, two potential EGR-1 binding sites at −15
and −55 and two potential Twist binding sites at −37
and −87 bp upstream from the start site were predicted
by the same software. Additionally, other binding sites
in the E-cadherin promoter for transcription factors
such as Snail have been reported [32]. The two













Figure 1 WT1 and E-cadherin mRNA expression in prostate cancer (PCa) cells. RNA was isolated from RWPE-1, LNCaP and PC3 cells, reverse
transcribed and (A) WT1 and (B) E-cadherin transcript levels were measured using TaqMan qRT-PCR. Values were normalized to 18S transcripts
levels and data are presented relative to the non-neoplastic prostate epithelial cell line RWPE-1. Experiments were done in triplicate and
reproduced twice. Student t-test was performed and significance was determined by comparing expression of WT1 (A) and E-cadherin (B) in PC3
cells with that of LNCaP cells (*p≤ 0.05, **p≤ 0.01). (C and D) E-cadherin mRNA expression levels in LNCaP (C) and PC3 (D) PCa cells transfected
with pCMV4 or GFP/WT1 expression construct were measured using TaqMan qRT-PCR. Values were normalized as described in (A and B). Data
are presented relative to pCMV4 transfected cells. Experiments were done in triplicate and reproduced three times. Student t-test was performed
and significance was determined by comparing pCMV4 to GFP/WT1 transfected cells (*p≤ 0.05). (E and F) E-cadherin mRNA expression in LNCaP
(E) and PC3 (F) PCa cells transfected with RISC or siWT1 RNA oligonucleotides were measured as described in (A and B). Data are presented
relative to RISC transfected cells. Significance was determined by Student t-test comparing RISC to siWT1 RNA oligonucleotides transfected cells
(*p≤ 0.05, **p ≤ 0.01) in three independent experiments.
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reported at −51 and −146 bp [32]. Multiple overlapping
WT1, EGR-1 and SP1 binding sites were predicted in
promoter regions of genes expressed in PCa epithelial
cells [33]. Our previous bioinformatics studies also
identified an evolutionarily conserved region containing
a potential overlapping WT1 and EGR-1 binding site in
the E-cadherin promoter [33]. To test whether the
region of the E-cadherin promoter containing WT1
sites was functional in PCa cells, Chromatin Immuno-
precipitation (ChIP) was performed. LNCaP and PC3
cells were transfected with the pGFP/WT1 expressionconstruct [34] to increase the levels of –KTS isoform
and enhance potential binding to the native chromatin
of LNCaP and PC3 cells. Chromatin of PC3 (Figure 2B)
and LNCaP (Figure 2D) cells was immunoprecipitated
with anti-WT1 antibodies and amplified by endpoint
PCR using primers (Figure 2A) designed to flank the
regulatory region of the E-cadherin gene containing
three WT1 potential binding sites. Additionally Syber-
green (Agilent, La Jolla, CA) quantitative real-time PCR
(qRT-PCR) analysis of the E-cadherin promoter region
was performed to validate and quantify representative








































Figure 2 WT1 binds to E-cadherin promoter in vivo. (A) Schematic diagram of E-cadherin promoter with transcription factors potential
binding sites: WT1 EGR-1 , Snail , Twist , SP1 . Positions of potential WT1 binding sites are listed and arrows indicate the
location of PCR primers used for amplification of chromatin. ChIP assays were performed with chromatin from PC3 (B) and LNCaP (D) cells. Cells
were transfected with GFP/WT1 construct and harvested after 48 hours. Chromatin was crosslinked and then immunoprecipitated with either IgG
(negative control), WT1 (B, D) or SP1 (positive control) (D) antibody. Input or immunoprecipitated DNA was amplified by endpoint PCR, as
described in Methods, using primers that amplify a 210 bp region of the E-cadherin proximal promoter. (B and D) Amplified products were
analyzed by gel electrophoresis and representative images are shown. (C and E) Sybergreen qRT-PCR was performed to quantify the WT1
immunoprecipitated DNA from PC3 (C) or LNCaP (E) cells. Experiments were reproduced twice with different chromatin preparations and
representative qRTPCR results are shown as fold enrichment compared to IgG.
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chromatin preparations from both cell lines were also
analyzed for confirmation of binding initially using the
endpoint PCR method and then validating by qRT-PCR
with similar results (data not shown). Specificity of
WT1 binding was assessed by endpoint PCR using
primers that flanked a region lacking potential WT1
binding sites, located ~1kb upstream of the transcrip-
tional start site (Additional file 1: Figure S1). These
results demonstrate specific in vivo DNA binding by
WT1, a prerequisite for WT1 mediated regulation of
the E-cadherin gene expression in PCa cells.
To determine whether WT1 transcriptionally regulates
E-cadherin promoter activity, a reporter construct con-
taining the region 403 bp upstream of the E-cadherin
transcription start site was cloned from genomic DNA, as
described in methods. To analyze the effect of overexpres-
sion of WT1 on the E-cadherin proximal promoter, the
E-cadherin reporter construct (Figure 3A) was co-
transfected along with increasing doses of GFP/WT1
expression construct in PC3 cells and luciferase activity
was measured as described in methods. As shown inFigure 3B, WT1 repressed the E-cadherin proximal
promoter in a dose dependent manner, with 500 ng of
GFP/WT1 achieving a greater than 50% reduction of the
promoter activity. These results together with gene ex-
pression studies, suggested that WT1 mediated repression
of E-cadherin could maintain low levels of expression of
E-cadherin in PCa cells. To confirm the effect of WT1
overexpression on the E-cadherin proximal promoter, the
reporter construct was transiently co-transfected along
with GFP/WT1 expression construct in both PC3
(Figure 3C) and DU145 (Figure 3D) cells and luciferase
activities were measured. As shown in Figure 3C and 3D,
WT1 repressed the activity of the proximal −403 bp
E-cadherin promoter by 5-fold in PC3 cells and 2-fold in
DU145 cells. These results confirmed that WT1 regulated
the activity of the E-cadherin proximal promoter at the
transcriptional level, but did not locate the specific WT1
binding sites involved.
Since three potential WT1 binding sites were identi-
fied in the E-cadherin promoter, it was necessary to
determine which one mediated the decreased activity of






Figure 3 WT1 represses E-cadherin proximal promoter. (A) Schematic diagram of the E-cadherin proximal promoter with 3 potential WT1
binding sites. (B) Effect of WT1 on E-cadherin promoter was tested in a dose response in PC3 cells. 250 ng of the E-cadherin proximal promoter
reporter construct was cotransfected either with pCMV4 or GFP/WT1 expression construct at 0, 250, 500 and 750 ng concentrations. DNA
concentrations were held constant by adding increasing amounts of pCMV4 and reporter activity analyzed as described in methods. (C and D)
E-cadherin proximal promoter reporter construct was cotransfected either with pCMV4 or GFP/WT1 expression construct in PC3 (C) and DU145
(D) cells. Luciferase activity was measured and normalized to protein concentration. Data are reported relative to luciferase activity of pCMV4
transfected cells. Experiments were repeated three times in triplicate. Significance was determined by student’s t-test comparing GFP/WT1
transfected cells to pCMV4 transfected (*p≤ 0.05, ***p≤ 0.001).
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E-cadherin promoter repression, site directed mutagen-
esis was performed on the −403 proximal promoter
(Figure 4A), as described in methods, using primers con-
taining the altered sequence (Table 1). Cotransfection
assays of the proximal promoter construct with the
mutated −146 site, showed that mutation of the WT1
binding site at-146 bp, eliminated the GFP/WT1 mediated
repression of the E-cadherin promoter activity in PC3 cells
(Figure 4B). These results were confirmed in another PCa
cell line, DU145, (Figure 4C) and showed that the −146 bp
WT1 binding site was required for the repression of the
proximal E-cadherin promoter by WT1. To determine
whether the additional WT1 binding sites located within
the G-rich core promoter might also contribute to WT1
mediated repression of the E-cadherin promoter, site-
directed mutagenesis was performed as described above.
Primers containing the altered sequences for either the
−15 or −51 bp WT1 binding sites (Figure 4D) were
designed (Table 1). The mutant core promoter constructs
were transiently cotransfected along with GFP/WT1
expression construct and luciferase activity was measured.
Despite mutation at either the −15 bp or the -51bp WT1binding sites in the −108 E-cadherin core promoter
construct, co-transfection with GFP/WT1 construct, fully
repressed the E-cadherin promoter activity (Figure 4E).
These results showed that neither of these two WT1 bind-
ing sites in the core promoter were required for repression
of the E-cadherin promoter by WT1. Taken together, these
results suggest that the WT1 binding sites in the core pro-
moter do not contribute to the repression of E-cadherin
promoter activity by WT1, rather, the −146 bp site in the
proximal promoter mediates E-cadherin expression in
PCa cells.
WT1 alters migration of PCa cells
Having identified the WT1 site that mediated the repres-
sion of E-cadherin, a cell adhesion molecule involved in
migration, it was necessary to test the effect of WT1 on
cell migration. Silencing of WT1 expression has been
shown to inhibit migration of human umbilical vascular
endothelial (HUVECs) cells [35]. Since knock-down of
WT1 increased E-cadherin mRNA levels in PCa cells
(Figure 1E and 1F), and E-cadherin is lost during EMT
when cells increase their migratory potential, we tested
the affect of WT1 on cell migration. A wound-healing
* 






Figure 4 WT1 binding site located at −146 bp is required for E-cadherin promoter repression. (A) Schematic diagram of the E-cadherin
proximal promoter showing the −146 bp WT1 binding site (box). (B) PC3 and (C) DU145 cells were transiently cotransfected with GFP/WT1 and
either with wild type or mutant proximal promoter containing a mutated −146 WT1 binding site. (D) Schematic diagram of the E-cadherin core
promoter showing −15 and −51 bp WT1 binding sites (boxes). (E) PC3 cells were transiently cotransfected with GFP/WT1 and either with wild
type or mutant core promoters containing a mutated −15 or −51 WT1 binding site. Luciferase activity was measured and normalized as
described in Figure 3. Experiments were repeated three times in triplicate. Data are reported relative to luciferase activity of pCMV4. Significance
was determined by student’s t-test comparing GFP/WT1 transfected cells relative to pCMV4 transfected cells (***p ≤ 0.001) in three independent
experiments.
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ther RISC or siWT1 RNA oligonucleotides or MOCK
transfected. The confluent monolayer was scratched
72 hours after transfection and cells were allowed to





-15 bp (a) F 50 –CTGGCTGCAGCCACGCATTTCCTCTCAGTGGCGTC-3′
R 50 – GACGCCACTGAGAGGAAATGCGTGGCTGCAGCCAG-3′
-51bp (a) F 50- CAATCAGCGGTACGGTTTGCGGTGCTCCGGGGC-3′
R 50- GCCCCGGAGCACCGCAAACCGTACCGCTGATTG-3′
-146bp (b) F 50- CGTCTATGCGAGGCCGTTTGTTCGGGCCGTCAGCTCCG-3′
R 50- CGGAGCTGACGGCCCGAACAAACGGCCTCGCATAGACG-3′
(a) Primers used to mutate the −15 and −51 bp WT1 binding sites on the
E-cadherin −108 core promoter.
(b) Primers used to mutate the −146 bp WT1 binding site on the E-cadherin
−403 proximal promoter.16 hours after transfection (Figure 5A) and images
analyzed by T-Scratch software [39] to determine the
percentage of wound remaining open at 16 hours com-
pared to 0 hour. The results were reproduced twice and
showed that siWT1 RNA oligonucleotides decreased
the migration of PC3 cells 4.4-fold compared to RISC
control transfection (Figure 5B). Representative samples
of RISC control or siWT1 RNA transfected cells were
analyzed by qRT-PCR and E-cadherin mRNA levels
were increased by 1.9-fold when WT1 was knocked
down by 83% (data not shown). Elevated E-cadherin
expression in siWT1 RNA transfected cells was consist-
ent with the reduced migration observed.
To validate the wound healing assay results, PC3
cells were transfected with siWT1 RNA or RISC oligo-
nucleotides or MOCK transfected, and after 72 hours,
cells were harvested for a transwell migration assay.
Cells were allowed to migrate for 6 hours, then six
images of stained inserts were taken (Figure 5C) and







Figure 5 WT1 affects PCa cell migration. (A) A wound healing assay was performed after transfection with siWT1 RNA or RISC oligonucleotides
or MOCK in PC3 cells. Migration potential was measured as described in methods. Monolayers were examined with an Olympus 1 × 70
microscope at 100X magnification and photographed at 0 and 16 hours after wounding. Representative images are shown and the bar
represents 100 μM. (B) Six images per treatment were measured and analyzed by TScratch software (39) comparing open area at 16 hours to that
at 0 hours. Values are presented as percent of open area of monolayers remaining at 16 hours compared to 0 hours and significance was
determined by student t-test (**p≤ 0.01,***p≤ 0.001) in two independent experiments. (C) PC3 cells were transfected as described in (A) and
placed in the upper chamber and allowed to migrate for 6 hours as described in methods. Representative images of hematoxylin stained
membranes containing migratory cells are shown at 100x magnification. (D) Migratory cells were counted in six images per treatment and data
are presented as average number of migratory cells per chamber. (E) LNCaP cells were transfected with pCMV4 or GFP/WT1 expression construct
as described in Figure 1. Transfected cells were placed in the upper chamber and allowed to migrate for 48 hours as described in methods. (F)
Data are presented as per panel D and significance was determined by student t-test (**p≤ 0.01,***p≤ 0.001) comparing siWT1 RNA transfected
relative to RISC transfected PC3 cells (D) and GFP/WT1 transfected relative to pCMV4 transfected LNCaP cells (F) in two independent experiments.
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decreased the average number of migrating PC3 cells by
50%, compared with RISC transfected, and by 60% com-
pared with MOCK (Figure 5D). Representative samples
were analyzed by qRT-PCR and E-cadherin mRNA
levels were increased by two-fold when WT1 was
knocked down by 88% (data not shown). Since siWT1
RNA decreased the migration of PC3 cells, we askedwhether the converse, overexpression of WT1, would
increase migration of LNCaP cells. LNCaP cells were
transfected with pCMV4 or GFP/WT1 expression vec-
tors and after 48 hours, cells were harvested for trans-
well migration assay as described. Cells were allowed to
migrate for 48 hours before inserts were removed, pro-
cessed and six photographs taken (Figure 5E) to calcu-
late averages for pCMV4 transfected or GFP/WT1
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that overexpression of WT1 increased migration of
LNCaP by 3-fold compared with pCMV4 transfected
LNCaP cells. These results suggested that WT1 expres-
sion was required for the high migratory potential of
PC3 cells and loss of WT1 dampened cell migration.
Conversely, increased expression of WT1 was suffi-
cient to enhance the low migratory potential of
LNCaP cells. Overall these findings link WT1’s role in
repression of E-cadherin expression to suppression of
cell-cell adhesion and increased migratory potential.
Evidence that WT1 mediated repression by binding
the E-cadherin promoter in vivo and transcriptionally
regulated the proximal promoter in vitro supports the
importance of WT1 in PCa cell migration. Thus,
overexpression of WT1 both suppresses expression
of the adhesion molecule, E-cadherin, and enhances
cell migration.
Discussion
In the present study we have provided evidence in sup-
port of WT1 transcriptionally repressing E-cadherin in
PCa cells. First, we observed an inverse relationship of
WT1 and E-cadherin mRNA levels in PC3 and LNCaP
cells. Secondly, overexpression of WT1 decreased
E-cadherin mRNA levels; and suppression of WT1
expression increased E-cadherin mRNA levels. The
titration of WT1 levels by transfection altered both
E-cadherin expression and the ability of these cells to
migrate. Overexpression of WT1 -KTS isoform, and not
other WT1 isoforms, has also been proven to increase
migration and invasion in human ovarian cancer cells
[36]. Finally, the mechanism whereby WT1 was able to
repress E-cadherin promoter activity in PCa cell lines
was examined. We identified two new potentialWT1
binding sites in the E-cadherin promoter and found that
WT1 bound to the E-cadherin promoter in chromatin
of both PC3 and LNCaP cells in vivo. Specifically, we
examined a 220 bp region predicted to have three WT1
binding sites. Although the WT1 binding sites were too
closely spaced to resolve single site binding, using site-
directed mutagenesis we demonstrated the requirement
of the newly identified −146 bp WT1 binding site for
the repression of the proximal E-cadherin promoter.
Overall, our study shows that WT1 is sufficient to
regulate E-cadherin mRNA levels, and our knock-down
results demonstrate the necessity of WT1 for regulated
E-cadherin expression in PCa cells. Importantly, the
biological effect of WT1 mediated changes in E-cadherin
levels in these prostate cancer cells lines was altered
migration, a key step in metastasis.
One of the hallmarks of cancer is the ability to invade
and metastasize [37], traits that require the EMT process
and E-cadherin is one of the most important epithelialmarkers lost in EMT. In the present study, we have
shown higher E-cadherin mRNA levels in LNCaP cells
compared to PC3 cells, and this is similar to reported
levels of E-cadherin protein expression in the same cell
lines [31]. In contrast to E-cadherin levels, our results
showed that WT1 mRNA levels are higher in PC3
compared to LNCaP cells. Thus, the inverse relationship
between WT1 and E-cadherin in LNCaP and PC3 cells
lines is consistent with the differences in the aggressive
phenotype between these two cell lines [38]. Our evi-
dence that WT1 transcriptionally repressed E-cadherin
in PCa cells, led us to examine the functional role of
WT1 in migration of PCa cells. Our findings that
overexpression of WT1 in LNCaP cells increased their
migration potential, is in agreement with those reported
in an ovarian cancer cell line [36] where the constitutive
expression of the WT1 A isoform promoted cell migra-
tion and invasion. However, that study was focused on
the effect of WT1 on the cell cytoskeleton, not on cell
adhesion molecules such as E-cadherin. Migration
is dependent upon disruption of CAMs including
integrins, selectins, members of the immunoglobulin
superfamily and cadherins. Through their interactions
with catenins, cadherins form a junctional complex with
cytoskeletal structures such as F-actin. Thus, WT1 may
affect migration by regulating components of the junc-
tional complex.
Not only did we find that WT1 over-expression was
sufficient to increase migration of LNCaP cells, but
inhibition of WT1 expression significantly reduced
motility of highly migratory PC3 cells. These results
showing that suppression of WT1 by siWT1 RNA
oligonucleotide transfection reduced migration of PC3
cells in transwell migration assays, were confirmed by
a wound-healing assay using the same siWT1 RNA.
This is in agreement with another study showing that
silencing of WT1 [35] in human umbilical vascular
endothelial cells (HUVECs) inhibited cell migration.
However, in HUVECs it appeared that WT1 regulated
the ETS-1 (E-twenty six) gene, a transcription factor
involved in angiogenesis and invasion. Thus our results
in PCa cells suggested a different mechanism whereby
WT1 enhanced migration directly through its effect on
E-cadherin transcription. This is the first report to
show that WT1 alters migration of PCa cells while
regulating one of the most important molecules
involved in the EMT process, E-cadherin. Taken
together, overexpression and silencing of WT1 signifi-
cantly affected PCa cell migration, supporting our hy-
pothesis that WT1 could behave as an oncogene and
promote the process of PCa metastasis.
The mechanism whereby WT1 enhances migration is
most likely mediated through transcriptional repression
of E-cadherin. WT1 mediated regulation of E-cadherin
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in murine fibroblasts, WT1 mediated upregulation of
E-cadherin in the murine and human E-cadherin
promoter [20]. In contrast, our results showed WT1
mediated downregulation of E-cadherin human pro-
moter. This discrepancy could be explained by cell
specificity since their study was done in normal murine
fibroblast cells, while we used human epithelial cancer
cells, which differ in their expression of cadherins. In
agreement with our findings, Martinez-Estrada et al.
[21]has shown downregulation of E-cadherin mRNA
and promoter activity in murine cardiac epithelial cells
overexpressing WT1. However, they also showed that
WT1 mediated indirect downregulation of E-cadherin
through the repressor Snail, which we did not find in
PCa cells, possibly reflecting differences between
normal murine cardiac epithelial cells vs human PCa
epithelial cells. Moreover, repression of E-cadherin in
cardiac epithelial cells was mediated via the core
promoter (at -51bp WT1 binding site). In contrast, our
results showed that E-cadherin regulation was mediated
through the proximal promoter containing the newly
identified WT1 binding site located at −146 bp
upstream from the transcription start site. We have
shown that WT1 repressed activity of the E-cadherin
proximal promoter in both PC3 and DU145 cells, and
mutation of the −146 bp WT1 binding site prevented
this repression, while mutation of sites in the core
promoter had no effect. Taken together, these results
suggest that the WT1 binding sites in the core promoter
do not contribute to the repression of E-cadherin
promoter activity by WT1, rather, the −146 bp site in
the proximal promoter is essential for WT1 mediated
E-cadherin repression in PCa cells. This is the first
report of the newly identified functional WT1 binding
site responsible for E-cadherin transcriptional repres-
sion and the first demonstrating the effect of WT1 on
migration of PCa cells. Although WT1 repressed ex-
pression of E-cadherin, a gene that must be suppressed
prior to cancer cell migration and is lost during EMT, it
is not clear to what extent WT1 contributes to EMT or
metastasis of prostate cancer cells. Certainly elevated
WT1 expression in prostate cancer compared to normal
prostate and BPH is consistent with its role as a regula-
tor of key steps in EMT and migration. Other reports
demonstrating a role for WT1 in EMT during epicardial
development suggest that its reactivation in prostate
cancer epithelial cells may also be associated with EMT
in cancer. Thus, WT1 appears to be linked to EMT, mi-
gration and possibly metastasis of prostate cancer cells.
Since metastasis is a very complicated process that is
still poorly understood, further studies are needed to de-
termine how WT1 is involved in EMT and metastatic
processes of PCa cells.Conclusions
We have shown that WT1 bound the E-cadherin
promoter in vivo; WT1 overexpression decreased, and
WT1 silencing increased, E-cadherin mRNA levels.
Moreover WT1 decreased E-cadherin promoter activity
and the −146 bp binding site was required for this de-
crease. Importantly, increased WT1 expression enhanced
migration of LNCaP cells and silencing WT1 decreased
migration of PC3 cells. Thus, we conclude that WT1 both
regulates E-cadherin levels and contributes to the migra-
tory potential of prostate cancer cells. These data are con-
sistent with an oncogenic function for WT1, enhancing
migration and metastasis of prostate cancer cells.
Methods
Cell lines and reagents
The LNCaP, PC3, and DU145 PCa cells and RWPE-1
non-neoplastic cells were obtained from the American
Type Culture Collection (ATCC, Manassas,VA). LNCaP
cells were grown in RPMI-1640 media supplemented
with 10% Fetal Calf Serum (FCS) and antibiotics, while
PC3 and DU145 cells were grown in DME-F12 media
with the same supplement. RWPE-1 cells were grown in
K-SFM supplemented with 0.05 mg/ml bovine pituitary
extract and 5 ng/ml EGF. All cells were maintained in
5% CO2 at 37°C.
Transfection
For overexpression of WT1, LNCaP and PC3 cells were
grown in 35mm tissue culture dishes until 80% conflu-
ent. Cells were transfected either with empty expression
vector as a control, pCMV4, (Promega, Madison, WI)
or the cytomegalovirus (CMV) promoter-driven pGFP/
Wt1(A) expression construct encoding the murine Wt1
protein (lacking both KTS insertion and exon 5) fused
at the amino terminus to the Green Fluorescent Protein
[34]. Cells were transfected with lipofectamine 2000
(Invitrogen, Carlsbad, CA) in a 1:3 DNA/lipid ratio as
per manufacturer’s recommendations. The cells were
incubated for 5 hours in antibiotic-free media, then the
transfection medium was replaced with complete
medium and after 48 hours cells were harvested for
RNA isolation or migration assays. Murine Wt1 primers
were used to confirm overexpression of the murine
GFP-Wt1 expression construct (Table 2).
For WT1 silencing, LNCaP and PC3 cells were grown
in 35mm tissue culture dishes until 50–60% confluent.
Cells were transfected with DharmaFECT#2 (Thermo
Scientific, Lafayette, CO) and either 50nM RISC (control,
non-targeting siRNA oligonucleotides with impaired
ability for RISC interaction) or siWT1 RNA specific
oligonucleotides designed to target WT1 (Dharmacon) or
MOCK (without oligonucleotides or transfection reagent).
Initially pools of si RNA oligonucleotides were tested
Table 2 TaqMan and Sybergreen qRT-PCR primer sets
used for expression analyses
Functional Class Gene Sequence
Housekeeping
gene
18S normalizer (a) Hs9999990_s1









R 50 CATGGGATCCTCATGCTTG 30
Snail
(human) (b)





(a) TaqMan probes used to amplify E-cadherin gene.
(b) Sybergreen primers used to amplify murine Wt1 and human WT1 or Snail
genes.
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Primarily, results for silencing by si WT1 RNA oligo-
nucleotide # 7 are shown in this study, but where stated,
results were confirmed by si WT1 RNA # 8. The trans-
fections were performed in antibiotic free media as
described above, but cells were harvested after 72 hours
of treatment for RNA isolation, migration or wound
healing assays. Human WT1 primers were used to confirm
knock-down of endogenous human WT1 expression by si
WT1 RNA (Table 2).
RNA isolation and quantitative real time PCR
RNA was isolated from confluent cells using the GenElute
Mammalian Total RNA Miniprep Kit following the
manufacture’s recommendations (Sigma-Aldrich, St Louis,
MO). RNA concentrations were measured in a NanoDrop
ND-1000 Spectrophotometer (Nanodrop Technologies,
Inc, Wilmington, DE) and 1μg RNA was reverse tran-
scribed using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems ABI, Foster City, CA).
Quantitative Real Time PCR (qRT-PCR) was per-
formed in triplicate using TaqMan Universal Master
Mix (ABI, Foster City, CA) and E-cadherin and 18S
normalizer TaqMan human probes (Table 2). Ten nano-
grams of cDNA samples were amplified using an ABI
7000 thermocycler. Amplification conditions were 95°C
for 10 minutes, and 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. After normalizing E-cadherin to
18S gene expression, the comparative Ct method was
used to analyze gene expression differences between
cells transfected with pCMV4 or GFP/Wt1. Student t-
test was used to analyze the significance.
qRT-PCR was also performed using Brilliant II Fast
Syber Green Master Mix (Agilent Technologies, La
Jolla, CA) and GAPDH (normalizer), Wt1, WT1 orSnail primers (Table 2). Each sample was assayed in
triplicate as described above, but using Stratagene
3000MxPro thermocycler (Agilent Technologies, La
Jolla, CA). Amplification conditions for WT1 were 95°C
for 2 minutes and 40 cycles of 95°C for 5 seconds and
60°C for 20 seconds. Data were analyzed as described
above, but normalizing to GAPDH and comparing cells
transfected with RISC to those transfected with siWT1
RNA oligonucleotides. Student t-test was used to
analyze the significance.
Chromatin immunoprecipitation (ChIP)
LNCaP and PC3 cells were grown until ~80% confluent
and then transfected with a GFP/Wt1 expression con-
struct as described above. After 48 hours, cells were
harvested for chromatin analysis as recommended by
manufacturer, (Millipore EZ-Magna ChIP, Temecula,
CA) and described previously [33]. After cross-linking
with a 1% formaldehyde solution (pH 4), cells were
then washed with cold PBS containing protease inhibi-
tors cocktail (Millipore, Temecula, CA). Chromatin was
sheared by sonication at medium power using six cycles
of 10 seconds of sonication followed by 30 seconds on
ice using a Microson Ultrasonic Cell Disruptor (Misonix
Incorporated, Farmingdale, NY). Sheared chromatin
was analyzed by gel electrophoresis and chromatin of
200–1000 bp was tested. Sheared chromatin was
suspended in protein G magnetic beads with either 5 μg
of anti-SP1 or 1 μg of anti-Pol II antibodies (as positive
controls) or 1 μg of mouse IgG fraction (negative
control) (Millipore, Temecula, CA) or a mixture of
anti-WT1 antibodies containing both C19 and N18
antibodies (Santa Cruz Technologies, Santa Cruz, CA)
and rocked overnight at 4°C. The magnetic beads-
Ab-protein-chromatin complexes were washed and
incubated with proteinase K as per manufacturer’s
recommendation (Millipore, Temecula, CA). Eluted
chromatin was purified using DNA purification columns
and chromatin was amplified using specific E-cadherin pri-
mers (−180 Forward 50-AACTCCAGGCTAGAGGGTCA-
30; +31 Reverse 50-TCACAGGTGCTTTGCAGTTC-30)
that flanked three potential WT1 binding sites in the
promoter region of E-cadherin. Endpoint PCR was
performed using the following PCR conditions: 94°C for
2 minutes, 34 cycles of 94°C for 20 seconds, 59°C for
30 seconds, 72°C for 30 seconds and final extension at
72°C for 2 minutes. The 210 bp PCR products were
separated by electrophoresis and visualized by ethidium
bromide in a 1% agarose gel. Validation of the endpoint
PCR was done by Sybergreen qRT-PCR as described above,
using same primers as for endpoint PCR. All ChIP experi-
ments were done at least twice with different chroma-
tin preparations and tested in two different cell lines.
To confirm specificity of WT1 binding, amplification
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tive control primers located approximately 1 kb from
the transcription start site (−1015 Forward 50-
ACGCCTGTAATCCAACACTTCAGG-30 and −714
Reverse 5-AAATTAGGCTGCTAGCTCAGTGGC-30)
and flanking a region devoid of potential WT1 binding
sites.
Luciferase assays
Cells were transfected in a 1:3 DNA/lipid ratio as
described above. For empty vector control wells, 750 ng
of pCMV4 (Promega, Madison WI) was used along
with 250 ng of E-cadherin luciferase construct. For ex-
perimental wells, 500 ng of GFP/Wt1 expression con-
struct along with 250 ng of E-cadherin luciferase
construct and 250 ng of empty vector expression con-
struct pCMV4 was used (to bring total DNA to 1μg per
well). After 48 hours cells were harvested for measure-
ment of luciferase activity using passive lysis buffer
(Promega, Madison WI). Lysates were centrifuged and
the supernatant was analyzed using luciferase assay
system (Promega, Madison WI) and activity was mea-
sured in a Turner luminometer 20/20 (Turner Biosystems,
Sunnyvale, CA). Protein concentrations were calculated
using bicinchoninic acid (BCA) method as described
(Thermo Scientific Pierce, Rockford, IL). Promoter activity
was normalized to protein concentration for each well and
represented by relative light units (RLU) of luciferase activ-
ity. Experiments were performed in triplicate and repro-
duced at least 3 times.
Cloning of the E-cadherin proximal promoter construct
The core (−108 + 125) E-cadherin promoter reporter con-
struct was purchased from Addgene (Cambridge, MA),
however, the larger proximal (−403 + 125) E-cadherin pro-
moter was cloned in the PGL3 basic luciferase vector
(Promega, Madison WI) using PCR amplified DNA. The
primer sequences used were: Forward 50 - GAGGTACCA
GTGAGCTGTGATCGCAC-30 and Reverse 50 -GGA
GCTCGAACTGACTTCCGCAAGCTC-3′. The forward
primer contained the KpnI site and the reverse primer
contained the SacI site. Endpoint PCR was performed
using Applied Biosystems reagents, as described for ChIP
analysis, except that 5% DMSO was added to reduce
secondary structures in GC-rich DNA. The following PCR
conditions were used: 95°C for 5 minutes, 35 cycles of
95°C for 1 minute, 62°C for 1 minute, 72°C for 1 minute
and final extension at 72°C for 5 minutes. Both the PGL3
basic luciferase vector and purified PCR products were
digested with KpnI and SacI restriction enzymes, ligated,
then after transformation, the identity of the purified plas-
mid was confirmed by sequencing. Activity of E-cadherin
promoter constructs was tested by transfection and luci-
ferase assays as described above.Site directed mutagenesis
Several WT1 binding sites in the E-cadherin promoter
were mutated using the QuickChange Site-Directed Muta-
genesis Kit (Stratagene, Agilent Technologies, Santa Clara,
CA) and primers containing the desired mutations (shown
in Table 1). PCR was performed using either the E-
cadherin core (−108) or proximal (−403) reporter con-
structs as templates along with the appropriate mutant
primers and 5% DMSO (to reduce secondary structures).
The following PCR conditions were used: 95°C for 30 sec-
onds, 18 cycles of 95°C for 30 seconds, 68°C for 1 minute,
68°C for 6 minutes. After amplification, parental strands
were digested by DpnI, which degrades parental methy-
lated DNA, and XL1-Blue supercompetent cells were
transformed with newly synthesized mutant DNA. Plas-
mid DNA was isolated, purified (Qiagen, Valencia, CA)
and sequenced to verify that the correct base pairs were
changed. The effect of each mutation was tested by luci-
ferase assays as described earlier.
Migration assay
PC3 cells were transfected with either RISC or siWT1
RNA oligonucleotides or MOCK as described above.
LNCaP cells were transfected with either pCMV4 empty
vector or GFP/Wt1 expression construct as described
above. After 72 hours (PC3 cells) or 48 hours (LNCaP
cells) of incubation, migration assays were performed
using ThinCerts migration inserts with 8μm pore size
(Bioexpress, Kaysville, UT). Briefly, 2 × 105 transfected
cells in serum free media were added to the top chamber
of the insert, while the bottom chamber contained media
with 10% FBS providing the chemoattractant signal. The
cells were allowed to migrate for 6 hours (PC3 cells) or
48 hours (LNCaP cells), then inserts were removed and
the remaining non- migrating cells on the upper surface
of the membrane were removed with a cotton swab. The
cells that migrated to the lower surface of the membrane
were fixed with 4% formaldehyde and stained with Harris
Hematoxylin Solution (Sigma Aldrich, St. Louis, MO).
After washing, the membrane was peeled off the plastic
inserts, placed on glass microscope slides and mounted
using HistoChoice mountaing media (Amresco, Solon,
OH). Migrating cells were examined by microscopy at
200X magnification with Olympus 1 × 70 microscope
(Center Valley, PA), then pictures were taken of six differ-
ent randomly selected fields and migrating cells were
counted manually. The average number of migratory cells
for each transfection condition was calculated. T-test was
used to determine significance. Migration assays in both
cell lines were reproduced twice. Additionally, to verify
efficacy of siWT1 RNA oligonucleotides, RNA was also
collected from representative samples of the above trans-
fected PC3 cells and qRT-PCR analysis of both WT1 and
E-cadherin expression was done as described above.
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PC3 cells were transfected with either RISC or siWT1
RNA oligonucleotides or MOCK as described above.
After 72 hours of treatment, transfected cells formed a
confluent monolayer and a 200μl pipette tip was used
to scratch a “wound” into the confluent monolayer.
Pictures were taken as described above, but at 100X
magnification, at both 0 and 16 hours after the
“wounding” to provide a comparison of migration over
time. TScratch software [39] was used to analyze six
images, measuring the differences in migration between
MOCK, RISC and siWT1 RNA oligonucleotides trans-
fected cells. Values were calculated as percentage (%) of
open area (“wound”) remaining at 16 hours compared
to 0 hour. T-test was performed to determine signifi-
cance. Wound healing assays in PC3 cells were repro-
duced twice with similar results. As described above, to
verify efficacy of siWT1 RNA oligonucleotides, RNA
was also collected from representative samples of the
above transfected PC3 cells and qRT-PCR analysis of
both WT1 and E-cadherin expression was done as
described above. Due to irregular growth of LNCaP
monolayers, analyses by TScratch software was not
attempted for GFP/Wt1 transfected LNCaP cells, thus
migration data in LNCaP cells was not confirmed by
wound healing assays.Additional file
Additional file 1: Figure S1. Top Panel: Positions of potential WT1
binding sties are listed and arrows indicate location of PCR primers for
amplification of chromatin. Bottom two panels: ChIP assays were
performed with chromatin from PC3 (left) and LNCaP (right) cells. Cells
were transfected with GFP/WT1 construct and harvested after 48 hours.
Chromatin was crosslinked and then immunoprecipitated with either IgG
(negative control), WT1 or SP1 antibodies. Input or immunoprecipitated
DNA was amplified by endpoint PCR using primers, shown as arrows in
top panel, that amplify a 300 bp region devoid of potential WT1 binding
sites and are located ~ 1Kb upstream of the transcriptional start site.
Amplified products were analyzed by gel electrophoresis and
representative images are shown.Abbreviations
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